CSIMarket
 


Corcept Therapeutics Inc  (CORT)
Other Ticker:  
 
 

CORT's EPS from Cont. Operations Growth by Quarter and Year

Corcept Therapeutics Inc's EPS from Cont. Operations results by quarter and year




CORT EPS from Cont. Operations (in $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 0.30 0.15 0.28 0.22
III Quarter September 0.31 0.32 0.26 0.19
II Quarter June 0.27 0.26 0.23 0.25
I Quarter March 0.15 0.22 0.20 0.26
FY   1.03 0.95 0.97 0.92



CORT EPS from Cont. Operations fourth quarter 2023 Y/Y Growth Comment
Corcept Therapeutics Inc achieved in the fourth quarter 2023, above Company average EPS from Cont. Operations surge of 102.92% year on year, to $ 0.30 .

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 10 other companies have achieved higher EPS from Cont. Operations growth. While Corcept Therapeutics Inc' s EPS from Cont. Operations doubling of 102.92% ranks overall at the positon no. 721 in the fourth quarter 2023.




CORT EPS from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 102.92 % -46.43 % 27.27 % -15.38 %
III Quarter September -3.13 % 23.08 % 36.84 % -17.39 %
II Quarter June 3.85 % 13.04 % -8 % 38.89 %
I Quarter March -31.82 % 10 % -23.08 % 62.5 %
FY   8.88 % -2.06 % 5.43 % 10.84 %

Financial Statements
Corcept Therapeutics Inc's fourth quarter 2023 EPS from Cont. Operations $ 0.30 CORT's Income Statement
Corcept Therapeutics Inc's fourth quarter 2022 EPS from Cont. Operations $ 0.15 Quarterly CORT's Income Statement
New: More CORT's historic EPS from Cont. Operations Growth >>


CORT EPS from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -1.81 % -53.13 % 7.69 % 15.79 %
III Quarter September 14.81 % 23.08 % 13.04 % -24 %
II Quarter June 80 % 18.18 % 15 % -3.85 %
I Quarter March 0 % -21.43 % -9.09 % 0 %
FY (Year on Year)   8.88 % -2.06 % 5.43 % 10.84 %




EPS from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #11
Healthcare Sector #51
Overall #721

EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
1016.01 % 75.89 % -47.19 %
(Mar 31 2018)   (Jun 30 2019)
EPS from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #11
Healthcare Sector #51
Overall #721
EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
1016.01 % 75.89 % -47.19 %
(Mar 31 2018)   (Jun 30 2019)

EPS from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Corcept Therapeutics Inc's Q/Q EPS from Cont. Operations Growth


EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
616.34 % 30.94 % -100 %
(Dec 31 2017)  


CORT's IV. Quarter Q/Q EPS from Cont. Operations Comment
In the IV. Quarter 2023 Corcept Therapeutics Inc reported decrease in EPS from Cont. Operations from the previous quarter by -1.81% to $ 0.30 , from $ 0.31 achived in the previous reporting period.

If you evaluate current shortcoming in the quarter, you should take into consideration, that usually IV. Quarter EPS from Cont. Operations appear to be weaker in contrast to the preciding period

Within Major Pharmaceutical Preparations industry 7 other companies have achieved higher EPS from Cont. Operations quarter on quarter growth. While Corcept Therapeutics Inc's EPS from Cont. Operations growth quarter on quarter, overall rank is 582.


EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #8
Healthcare Sector #47
Overall #582
EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #8
Healthcare Sector #47
Overall #582
EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
616.34 % 30.94 % -100 %
(Dec 31 2017)  


CORT's IV. Quarter Q/Q EPS from Cont. Operations Comment
In the IV. Quarter 2023 Corcept Therapeutics Inc reported decrease in EPS from Cont. Operations from the third quarter by -1.81% to $ 0.30 , from $ 0.31 declared in the previous reporting period.

As we analyse current shortcoming in the quarter, we must assume, that commonly IV. Quarter EPS from Cont. Operations appear to be weaker relative to the preciding period

Within Major Pharmaceutical Preparations industry 7 other companies have achieved higher EPS from Cont. Operations quarter on quarter growth. While Corcept Therapeutics Inc's EPS from Cont. Operations growth quarter on quarter, overall rank is 582.


Corcept Therapeutics Inc's 12 Months EPS from Cont. Operations Growth Year on Year


EPS from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative EPS from Cont. Operations 12 Months Ending $ 1.03 $ 0.88 $ 0.89 $ 0.88 $ 0.95
Y / Y EPS from Cont. Operations Growth (TTM) 8.47 % -18.33 % -12.56 % -10.92 % -1.88 %
Year on Year EPS from Cont. Operations Growth Overall Ranking # 613 # 380 # 612 # 549 # 728
Seqeuential EPS from Cont. Operations Change (TTM) 17.07 % -1.12 % 1.13 % -7.34 % -11.86 %
Seq. EPS from Cont. Operations Growth (TTM) Overall Ranking # 721 # 815 # 953 # 704 # 713




Cumulative EPS from Cont. Operations growth Comment
Although Corcept Therapeutics Inc's Annual EPS from Cont. Operations growth year on year were below company's average 75.89% , EPS from Cont. Operations announced in the Dec 31 2023 period, show improvement in EPS from Cont. Operations trend, to cumulative trailing twelve month growth of 8.47% year on year, from -18.33% in Sep 30 2023.

In the Healthcare sector 43 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While EPS from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 380 to 613.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
1016.01 %
75.89 %
-47.19 %
 

EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 11
Healthcare Sector # 44
Overall # 613

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
1016.01 %
75.89 %
-47.19 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 51
S&P 500 # 721
Cumulative EPS from Cont. Operations growth Comment
Although Corcept Therapeutics Inc's Annual EPS from Cont. Operations growth year on year were below company's average 75.89% , EPS from Cont. Operations announced in the Dec 31 2023 period, show improvement in EPS from Cont. Operations trend, to cumulative trailing twelve month growth of 8.47% year on year, from -18.33% in Sep 30 2023.

In the Healthcare sector 43 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While EPS from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 380 to 613.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
1016.01 %
75.89 %
-47.19 %
 


EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 11
Healthcare Sector # 44
Overall # 613

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
1016.01 %
75.89 %
-47.19 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 51
S&P 500 # 721




Other EPS from Cont. Operations Growth
Major Pharmaceutical Preparations Industry EPS from Cont. Operations Growth Trends and Statistics
Healthcare Sector EPS from Cont. Operations Growth Statistics
EPS from Cont. Operations Growth Trends for overall market
CORT's EPS from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking EPS from Cont. Operations Growth
Lowest Ranking EPS from Cont. Operations Growth
EPS from Cont. Operations Growth for CORT's Competitors
EPS from Cont. Operations Growth for Corcept Therapeutics Inc's Suppliers
EPS from Cont. Operations Growth for CORT's Customers

You may also want to know
CORT's Annual Growth Rates CORT's Profitability Ratios CORT's Asset Turnover Ratio CORT's Dividend Growth
CORT's Roe CORT's Valuation Ratios CORT's Financial Strength Ratios CORT's Dividend Payout Ratio
CORT's Roa CORT's Inventory Turnover Ratio CORT's Growth Rates CORT's Dividend Comparisons



Companies with similar EPS from Cont. Operations decrease for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %EPS from Cont. Operations for the quarter ending Dec 31 2023
Tenet Healthcare Corp147.66%$ 147.658 
Davita Inc 120.38%$ 120.379 
Vericel Corporation117.03%$ 117.031 
Iqvia Holdings Inc 110.58%$ 110.579 
Stryker Corp102.31%$ 102.306 
Alpha Pro Tech Ltd 102.01%$ 102.011 
Corcept Therapeutics Inc98.20%$ 98.198 
Quest Diagnostics Inc96.11%$ 96.115 
Intuitive Surgical Inc 86.05%$ 86.050 
Astrazeneca Plc81.13%$ 81.132 
Dr Reddy s Laboratories Limited76.47%$ 76.471 
3m Company72.40%$ 72.405 
Electromed Inc 66.67%$ 66.667 
Select Medical Holdings Corp65.65%$ 65.648 
Neurocrine Biosciences Inc 63.08%$ 63.082 
United Therapeutics Corporation60.16%$ 60.158 
Cytek Biosciences Inc 57.66%$ 57.659 
Abbott Laboratories55.26%$ 55.256 
Halozyme Therapeutics Inc 55.17%$ 55.172 
Tactile Systems Technology Inc 52.10%$ 52.101 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com